Tim McCarthy, Chairman of ImmuPharma PLC (LON:IMM) talks to Proactive Investors about the company’s £4.1 million raise from investors after an oversubscribed placing.
The new cash infusion is to be used to strengthen its balance sheet as negotiations take place with potential commercial partners for its flagship drug, Lupuzor.